Z Shah

Does Biomarker Use in Oncology Improve Clinical Trial Failure Risk? A Large-scale Analysis.

Parker JL, Kuzulugil SS, Pereverzev K, Mac S, Lopes G, Shah Z, Weerasinghe A, Rubinger D, Falconi A,
Program News, Research
Students in Study
A pre-COVID photo of some of the students involved in the study. From right: Rohan Tangri, Ashini Weerasinghe, Zain Shah, Kirill Pereverzev and Stephen Mac.
Z Shah
Zain Shah, Class of 2017

 

Cancer Medicine, 2021; 10(6):1955-1963. › 10.1002/cam4.38732

Impact factor: 3·4

Application relevance: This study provides the first systematic statistical evidence that biomarkers clearly increase clinical trial success rates in three different indications in oncology. Also, exploratory biomarkers, long before they are properly validated, appear to improve success rates in oncology. This study supports early and aggressive adoption of biomarkers in oncology clinical trials.